Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xin-Guan-2 formula (also known as Xinguan II decoction) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Guangdong Provincial Hospital of Chinese Medicine. It was formulated during the early stages of the COVID-19 pandemic to treat suspected cases of COVID-19 pneumonia. The formula consists of several herbal ingredients, including Ephedrae Herba, Semen Armeniacae Amarum, Gypsum Fibrosum, Semen Coicis, Atractylodis Rhizoma, Rhizoma Polygoni Cuspidati, Verbenae Herba, Pogostemonis Herba, Descurainiae Semen, Phragmitis Rhizoma, Exocarpium Citri Rubrum, and Glycyrrhizae Radix et Rhizoma. It is administered orally as a decoction to relieve symptoms, clear heat, resolve dampness, and support respiratory function in patients with viral pneumonia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xin-Guan-2 formula.